She approved it.
The room nodded.
No one owned it.
Three months into the Chief Medical Officer seat.
The deployment came to governance.
She read the validation.
The performance held.
She approved it.
For the first time
she felt like she had earned the seat.
Stanford tested the best clinical AI agents
on real medical record tasks.
The strongest were wrong on one in three.
In the eye, a scotoma is a blind spot.
Not darkness.
Nothing.
The defect is not that you see a gap.
The defect is that nothing looks missing.
The brain fills it in.
The world looks whole.
Governance has the same blind spot.
The deployment is approved.
The validation is clean.
The chart reads complete.
Nothing looks missing.
The seat is empty anyway.
The validation answered the technical question.
It never named the owner.
The question underneath
was never whether the AI was safe.
It was who owns the call
when it is not.
She approved the deployment perfectly.
She never saw the seat behind it was empty.
The gap was invisible
from the chair she sat in.
The Accountability Gap™ (TAG™)
does not close with a validation.
It closes when the deployment
has a named owner
before it reaches a patient.
You already know which deployment
you approved on a clean validation.
The only question is whether
anyone was named to own it
before it reached the bedside.
Mo Johnson, MD MBA is a cardiothoracic surgeon and the founder of GPe Research. Field Notes are short dispatches from the clinical AI accountability frontier, published alongside the MedicoVigilance™ newsletter at medicovigilance.org.
Follow the work on LinkedIn: linkedin.com/in/mo-johnson